New prediction model helps identify epilepsy risk after stroke

Researchers from 15 countries, led by Amsterdam UMC, have developed a way to predict which patients are at risk of epilepsy after a cerebral venous sinus thrombosis (CVT).

AstraZeneca’s rare blood disorder pill approved in Japan

AstraZeneca’s add-on pill for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) won its first approval in Japan, the company announced Friday. The drug, an

January 20, 2024

UCSF dementia experts to join peers at annual Clinical Trials on Alzheimer’s disease conference

Dementia experts from UC San Francisco will join their peers from around the globe at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in

October 20, 2023

Schwazze Q1 Revenue Was Flat From Q4 at $40 Million

Schwazze Announces First Quarter 2023 Financial Results Revenue Increases 26% to $40.0M Compared to $31.8M in Q1 2022 Income From Operations Grew to $5.6M Compared to ($4.8M) in Q1 2022 Adjusted

May 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.